Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
132 hedge funds and large institutions have $563M invested in Keryx Biopharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
5% more funds holding
Funds holding: 126 → 132 (+6)
2% less capital invested
Capital invested by funds: $574M → $563M (-$10.8M)
33% less call options, than puts
Call options by funds: $3.44M | Put options by funds: $5.14M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$4.78M |
| 2 |
BlackRock
New York
|
+$4.17M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$3.51M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.43M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$12.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |
| 3 |
Millennium Management
New York
|
-$2.96M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$1.59M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$948K |
KERX Hedge Fund Activity: Q3 2017 in Review
132 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2017, worth a combined $563M — down 1.9% from $574M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KERX positions and 9 closed out — a net gain of 7 holders — while 49 added to existing stakes and 34 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $4.78M. The largest seller was Consonance Capital Management, cutting an estimated $12.8M.
- 132 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2017, up from 126 in Q2 2017.
- Funds reported $563M of Keryx Biopharmaceuticals Inc stock for Q3 2017, down 1.9% quarter-over-quarter.
- 16 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2017 and 9 closed out, a net change of +7 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2017 was Russell Investments Group, an estimated $4.78M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2017 was Consonance Capital Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2017.